Clinical Trial

Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

Study acronym: ALSFUS003
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet (NGDH) FUS in adult participants with ALS.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-18.
Status change: Recruiting → Active, Not Recruiting 2026-07-10
Trial Details
NCT Number NCT07193953
Lead Sponsor Sunnybrook Health Sciences Centre
Collaborators: Focused Ultrasound Foundation
Conditions Amyotrophic Lateral Sclerosis, ALS
Enrollment 6 participants
Start Date 2025-04-15
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-14